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trial (Burris et al in 1998). Total treatment costs esti-
mates are based on chemotherapy, infusions, hospitalisa-
tions, visits to health care professionals and concomitant
medications. Resource utilisation data, derived from the
trial, were combined with unit cost data from various UK
sources. The time horizon is 18 months and costs relate
to 2000. A 6% discounting rate was applied. Effective-
ness was measured by: survival, progression-free survival,
and % of clinical benefit responders Extensive sensitivity
analysis was performed to test the robustness of the re-
sults. RESULTS: Total treatment cost per patient on
Gemzar was estimated at £3,569 and on 5-FU at £1,262—
the difference attributed mainly to higher drug acquisi-
tion costs. Gemzar was associated with an incremental
gain of 0.188 life years, 0.116 progression-free-life-years
and 19% of patients could be classifed as clinical benefit
responders. As such, relative to 5-FU, the incremental
cost-per-clinical-benefit-responder with Gemzar is £12,172,
the incremental cost-per-life-year-gained is £12,206 and
the incremental cost-per-progression-free-life-year gained
is £19,888. Sensitivity analyses showed that the results
did not vary significantly with changes of the parameters.
When 5-FU is administered by continuous infusion, the
cost per patient increases to £1,900 and the incremental
cost-effectiveness of Gemzar is improved. CONCLU-
SIONS: This economic evaluation demonstrates that
Gemzar consists a cost-effective alternative to an existing
therapy that is commonly used in the UK for treatment of
pancreatic cancer. The incremental cost-effectiveness of
Gemzar compares favourably with that of other treat-
ments funded by the NHS.
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OBJECTIVES: Lung cancer is a leading cause of morbid-
ity and mortality. Chemotherapy is a main treatment op-
tion but its availability in the UK is limited in comparison
to other countries and is not consistent across geographi-
cal regions. The present study reports on two economic
evaluations of Gemzar/cisplatin relative to: paclitaxel/
cisplatin, paclitaxel/carboplatin, docetaxel/cisplatin (eval-
uation 1); and vinorelbine/cisplatin (evaluation 2). METH-
ODS: The perspective is that of the UK-NHS. Informa-
tion was derived from randomised clinical trials (Schiller
et al 2000 (evaluation 1), Comella et al 2000 (evaluation
2)). Total treatment costs include: chemotherapy and in-
fusion, hospitalisations, visits to health care profession-
als, and concomitant medications. Resource utilisation
information was combined with unit cost data from vari-
ous UK sources. Costs relate to 2000 and were adjusted
with the NHS inflation index if necessary. The time hori-
zon for the estimation of costs is one year; hence dis-
counting was unnecessary. Treatment effectiveness is
mainly measured by time to disease progression and
overall survival. RESULTS: In the first evaluation the
cost per patient in the Gemzar/cisplatin, paclitaxel/cis-
platin, paclitaxel/carboplatin, docetaxel/cisplatin arms was
£5,537, £9,043, £8,444, and £5,779 respectively. Thus,
the Gemzar/cisplatin achieves cost savings up to £3506,
which is driven by lower chemotherapy costs. Progres-
sion-free-life-years for each treatment arm, in the order
presented above, were 0.375, 0.292, 0.300 and 0.275 re-
spectively. Thus, the Gemzar/cisplatin combination dom-
inates the other three combinations. In evaluation 2, a
conservative approach was used whereby the survival
outcome was assumed to be equivalent between Gemzar/
cisplatin and vinorelbine/cisplatin arms. However, the
cost in the Gemzar/cisplatin arm was £4,476 and in the
vinorelbine/cisplatin arm £5,047. Despite significant
changes to important parameters Gemzar with cisplatin
maintains dominance or achieves very low positive incre-
mental cost-effectiveness ratios, the maximum of which is
£1,200. CONCLUSIONS: Gemzar/cisplatin is less expen-
sive and equally or more effective than the other alterna-
tive regiments. Thus, on cost-effectiveness grounds, it
should be encouraged in the treatment of NSCLC pa-
tients in the UK.
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BACKGROUND: Prostate cancer is the most common
type of malignancy found in US male population and the
second leading cause of cancer fatality in men. PSA
screening is a common test in prostate cancer diagnosis.
This research investigates its cost-effectiveness. METH-
ODS: A cost-effectiveness model is constructed following
a cohort of patients aged 60 to 75 taken from a general
US population. Clinical outcomes, costs, and transition
state probabilities were derived from medical literature
and used to construct a Markov state probability model.
The analysis takes a societal perspective and all costs
were converted to 2000 dollars. Discount rate in base
case was 3%. The parameters in the base-case were as-
sessed for robustness using one-way sensitivity analysis.
RESULTS: We found that a screening program with
annual PSA testing starting at age 60 would result in
cost-effectiveness ratios of $8000 per QALY. One-way
sensitivity testing found the results to be very stable.
Threshold analysis revealed that screening ceased to be
cost-effective (CE ratio $50,000/QALY) only when
costs for procedures such as prostate surgery approached
$500,000 or prostate cancer was detected at high levels
(80% true positives in first year of testing, up from cur-
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rent 20%) in the population. CONCLUSIONS: The
model suggests that annual PSA screening of male popu-
lation for prostate cancer is extremely cost-effective,
given current data. Further research into outcomes of
prostate cancer is needed to estimate cost-effectiveness of
screening in various subpopulations. In particular, given
the long clinical progression of prostate cancer, more re-
search is required into outcomes and cost-effectiveness in
relatively healthy patients versus those burdened by seri-
ous co-morbidities.
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OBJECTIVES: To conduct an economic evaluation of an
open label, phase III randomized trial involving centers in
North America and Europe. METHODS: There were 239
and 235 patients in the liposomal doxorubicin (50mg/m2
every 4 weeks) and topotecan (1.5mg/m2 for 5 days every
3 weeks) arms, respectively. Overall median survival was
420 days and 397 days for liposomal doxorubicin and to-
potecan, respectively (hazard ratio  1.12 (90% CI
0.92,1.37; p  .34)). Because the outcomes were not clin-
ically different for the 2 groups, a cost minimization anal-
ysis was performed. Costs included were: study drug;
drug administration; and management of adverse events.
Actual mg of drug administered and frequency and sever-
ity of adverse events were obtained from the clinical trial.
Expert opinion was used to estimate the resources used in
the treating adverse events, and unit costs were based on
UK practice data. Further validation of the expert opinion
is currently underway. RESULTS: Severe (Grade III/IV)
toxicities were more frequent for liposomal doxorubicin
versus topotecan in terms of palmar-plantar erythrodyses-
thesia (PPE) (n  64 vs. 0), and stomatitis/pharyngitis (n 
32 vs. 2) but less frequent for thrombocytopenia (n  3
vs. 238), anemia (n  19 vs. 146), neutropenia (n  55
vs. 764) and fever (n  2 vs. 13). The average cost per pa-
tient was estimated to be EUR16,230 (95% CI 14,780 to
17,680) and EUR20,554 (95% CI 18,764 to 22,344) for
liposomal doxorubicin and topotecan, respectively. Per
patient cost for drug  administration were similar be-
tween the two groups, (EUR14,974 and EUR15,073); the
main differential in cost was management of anemia
(EUR407 and EUR2,219) and neutropenia (EUR57 and
EUR1,454) for the liposomal doxorubicin and topotecan
groups, respectively. CONCLUSIONS: In settings where
the current standard of care for platinum refractory or re-
sistant ovarian cancer is topotecan, liposomal doxorubi-
cin offers the potential for savings through reduction in
cost of adverse event management.
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Cost-utility analysis is rapidly becoming the standard
pharmacoeconomic measure in oncology. OBJECTIVE:
To compare paclitaxel (pac) and docetaxel (doc) in the
treatment of second line or greater metastatic breast can-
cer using a cost-utility analysis. METHODS: Utilities we
collected from 45 patients using eight modified Markov
modeled health states (Pharmacoeconomics, 1996;
60:504) describing metastatic breast cancer; the standard
gamble procedure was utilized to obtain utility. Costs
were collected prospectively from 31 patients in a single
outpatient center. Direct medical costs were collected
(e.g., all medications, physician/clinic/laboratory visits,
ER, hospitalizations, home health care, consultations,
special procedures, transfusions, phone calls, and miscel-
laneous) and costs were defined using Medicare reim-
bursement rates and AWP for drugs. Sensitivity analyses
are currently underway. RESULTS: The average cost per
cycle of chemotherapy was $4,298 and $2,869 for doc
and pac respectively. The mean utility score obtained
from patients was .78 and .76 for doc and pac respec-
tively. The utility scores suggest that doc offers 7.3 days
of perfect health when compared to pac. However, the
incremental cost-utility analysis (cost of doc  cost of
pac/QALY of doc  QALY of pac) indicates that the use
of doc costs $71,450 per Quality Adjusted Life Year
(QALY) when compared to pac. Another way to view
these results is that it costs $195.75 more per Quality Ad-
justed Day (QAD) to treat a patient with docetaxel.
CONCLUSIONS: Our results indicate that docetaxel is
more expensive ($4,298/cycle vs. $2,869/cycle) than pa-
clitaxel, and that metastatic breast cancer patients do not
perceive the drugs as being different (utility scores .76 for
pac and .78 for doc). This cost-utility analysis suggests
that the use of docetaxel over paclitaxel may not be justi-
fied in the treatment of metastatic breast cancer.
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OBJECTIVE: Chemotherapy-induced bone marrow tox-
icity is expensive because of the cost of managing compli-
cations of pancytopenia. Growth factors minimize these
complications. Economic analyses of growth factors typi-
cally focus on common, less serious outcomes, rather
